2024-10-07 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis: 

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical devices, and consumer packaged goods company. Its cumulative return over the period is 33.77%, lagging significantly behind the S&P 500 (VOO) which has returned 133.14%. The relative divergence, which measures the stock's performance against the S&P 500, is currently at -99.37, indicating that JNJ has underperformed the benchmark index by a significant margin.

**2. Recent Price Movements:**

* **Closing Price:** $160.29
* **5-day Moving Average:** $161.20
* **20-day Moving Average:** $163.72
* **60-day Moving Average:** $161.09

JNJ's price is currently trading below its 5-day, 20-day and 60-day moving averages, suggesting a potential downtrend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 19.93
* **PPO (Percentage Price Oscillator):** -0.38

The low RSI value of 19.93 suggests that the stock is currently in oversold territory. The negative PPO value of -0.38 also reinforces the downtrend observed in the price action. The recent 20-day relative divergence of -13.51 further indicates a short-term downward trend. The expected return for JNJ is 0.0%, suggesting no expected outperformance compared to the S&P 500 over the next 5 years. 

**4. Recent Earnings and Outlook:**

| Date     | EPS    | Revenue        |
|---------|--------|-----------------|
| 2024-07-25| 1.95   | 22.45 B$       |
| 2024-05-01 | 1.35   | 21.38 B$       |
| 2024-02-16 | 1.68   | 21.39 B$       |
| 2023-10-27 | 10.32  | 21.35 B$       |
| 2024-02-16 | 10.32  | 21.35 B$       |

JNJ's recent earnings have been mixed, with some quarters showing growth while others demonstrate decline.  The most recent earnings report for the quarter ending July 25th, 2024, showed an EPS of 1.95 and revenue of $22.45 billion.  While the earnings exceeded analysts' estimates, the revenue fell short. The company faces ongoing challenges from generic drug competition and the ongoing litigation related to its talcum powder products. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** JNJ's stock price has been impacted by concerns related to its pharmaceutical business, litigation costs, and slower-than-expected growth in the consumer health segment.
* **Analyst Opinions:** Analysts generally maintain a mixed outlook on JNJ, with some expressing optimism based on its strong cash flow and dividend yield, while others remain cautious due to the ongoing litigation and competitive pressures.
* **Performance Highlights:** JNJ has a strong dividend history and is known for its consistent performance. However, its recent underperformance and legal issues have overshadowed its positive attributes.

**6. Overall Analysis:**

JNJ's stock is currently underperforming the market, facing significant headwinds from litigation, competition, and slower growth. Despite its strong brand and dividend history, the stock is showing signs of weakness, reflected in its low technical indicators and recent price movements.  The stock is in oversold territory, but it is essential to monitor further developments regarding its litigation and its ability to overcome these challenges. 

**7. English Report:**

## **Johnson & Johnson (JNJ) Stock Analysis**

This report provides an in-depth analysis of Johnson & Johnson (JNJ) stock performance, recent price movements, technical indicators, and recent earnings. 

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical devices, and consumer packaged goods company. Its cumulative return over the period is 33.77%, lagging significantly behind the S&P 500 (VOO) which has returned 133.14%. The relative divergence, which measures the stock's performance against the S&P 500, is currently at -99.37, indicating that JNJ has underperformed the benchmark index by a significant margin.

**2. Recent Price Movements:**

* **Closing Price:** $160.29
* **5-day Moving Average:** $161.20
* **20-day Moving Average:** $163.72
* **60-day Moving Average:** $161.09

JNJ's price is currently trading below its 5-day, 20-day and 60-day moving averages, suggesting a potential downtrend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 19.93
* **PPO (Percentage Price Oscillator):** -0.38

The low RSI value of 19.93 suggests that the stock is currently in oversold territory. The negative PPO value of -0.38 also reinforces the downtrend observed in the price action. The recent 20-day relative divergence of -13.51 further indicates a short-term downward trend. The expected return for JNJ is 0.0%, suggesting no expected outperformance compared to the S&P 500 over the next 5 years. 

**4. Recent Earnings and Outlook:**

| Date     | EPS    | Revenue        |
|---------|--------|-----------------|
| 2024-07-25| 1.95   | 22.45 B$       |
| 2024-05-01 | 1.35   | 21.38 B$       |
| 2024-02-16 | 1.68   | 21.39 B$       |
| 2023-10-27 | 10.32  | 21.35 B$       |
| 2024-02-16 | 10.32  | 21.35 B$       |

JNJ's recent earnings have been mixed, with some quarters showing growth while others demonstrate decline.  The most recent earnings report for the quarter ending July 25th, 2024, showed an EPS of 1.95 and revenue of $22.45 billion.  While the earnings exceeded analysts' estimates, the revenue fell short. The company faces ongoing challenges from generic drug competition and the ongoing litigation related to its talcum powder products. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** JNJ's stock price has been impacted by concerns related to its pharmaceutical business, litigation costs, and slower-than-expected growth in the consumer health segment.
* **Analyst Opinions:** Analysts generally maintain a mixed outlook on JNJ, with some expressing optimism based on its strong cash flow and dividend yield, while others remain cautious due to the ongoing litigation and competitive pressures.
* **Performance Highlights:** JNJ has a strong dividend history and is known for its consistent performance. However, its recent underperformance and legal issues have overshadowed its positive attributes.

**6. Overall Analysis:**

JNJ's stock is currently underperforming the market, facing significant headwinds from litigation, competition, and slower growth. Despite its strong brand and dividend history, the stock is showing signs of weakness, reflected in its low technical indicators and recent price movements.  The stock is in oversold territory, but it is essential to monitor further developments regarding its litigation and its ability to overcome these challenges. 
